Legal status · United States
Is Apitegromab legal in the United States?
No. Apitegromab is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. Human evidence to date: Moderate.
Apitegromab in the United States at a glance
| Classification | Investigational, not approved |
|---|---|
| FDA approval status | Under FDA review for SMA (PDUFA September 30, 2026); investigational in obesity |
| Evidence level | Moderate (research strength: Strong) |
| Reviewed | Sep 2026 |
Classification and note come from the Apitegromab profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
Apitegromab is being studied in registered clinical trials but has not received FDA marketing approval in the United States.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What Apitegromab is
An antibody against latent myostatin, under FDA review for spinal muscular atrophy (decision due September 30, 2026) and shown to preserve 55% of the lean mass otherwise lost on tirzepatide.
Apitegromab binds the pro and latent forms of myostatin so it cannot be activated, releasing the brake on muscle growth. Scholar Rock filed it for spinal muscular atrophy; a 2025 complete response letter concerned a manufacturing site only, and the resubmission carries a September 2026 decision date.
Mechanism: Monoclonal antibody that binds pro/latent myostatin and prevents its activation, increasing skeletal muscle mass.
Regulatory history: Under FDA review for SMA (PDUFA September 30, 2026); investigational in obesity
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Apitegromab at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Apitegromab in other countries
Frequently asked questions
Is Apitegromab legal in the United States?
No. Apitegromab is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. Human evidence to date: Moderate.
Can I buy Apitegromab in the United States?
No approved product exists to buy. In the United States Apitegromab is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.
Is Apitegromab FDA approved?
No. FDA status: Under FDA review for SMA (PDUFA September 30, 2026); investigational in obesity. Current US classification: "Investigational, not approved". Evidence level: Moderate.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Apitegromab live on its compound profile.
Apitegromab profileThis page is general information about the regulatory status of Apitegromab in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.